- Home
- DMLP vs NBTX Comparison
DMLP vs NBTX Comparison
Compare DMLP & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMLP | NBTX |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DMLP | NBTX |
|---|---|---|
| Price | $27.00 | $31.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 158.3K | 24.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $152,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | $22.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.85 | $2.95 |
| 52 Week High | $30.51 | $31.49 |
Technical Indicators
Market Signals| Indicator | DMLP | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.84 | 74.91 |
| Support Level | $27.09 | $20.11 |
| Resistance Level | $28.20 | N/A |
| Average True Range (ATR) | 0.64 | 1.69 |
| MACD | 0.06 | 0.63 |
| Stochastic Oscillator | 98.78 | 82.42 |
Price Performance
Historical ComparisonAbout DMLP Dorchester Minerals L.P.
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.